Interestingly, repetitive pre-administration of RvD2 (i.t., 500 ng) suppressed the overexpression of IL-17, CXCL1 as well as GFAP proteins in the dorsal horn following sarcoma exposure (p < 0.05, n = 4; Figure 4A–C). Here, IL17A is linked to sarcoma.